New Analyses from the IMPROVE-IT Study with VYTORIN (ezetimibe and simvastatin)
September 01, 2015 at 09:06 AM EDT
Merck (NYSE: MRK), known as MSD in the United States and Canada, today announced results from new analyses from the IMPROVE-IT study. ...
